Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc. is poised for substantial revenue growth due to the high unmet medical need in the management of septic shock, particularly with the expected increase in demand for Giapreza as treatment guidelines are updated. The company has also reported significant sales growth for Xacduro, which is projected to reach a run rate of $95.3 million by 3Q25, reflecting strong commercial momentum and substantial y/y growth rates. Furthermore, the combination of durable patent protection and improvements in treatment safety profiles enhances Innoviva's prospects within the healthcare market.

Bears say

Innoviva Inc faces significant challenges in its healthcare portfolio, particularly within the critical care and infectious disease sectors, as evidenced by the high mortality rates associated with infections such as MRSA and CABP, which impact the financial viability of its products. The company's reliance on successful commercialization of its marketed products and new launches, such as ZEVTERA and zoliflodacin, is threatened by various risks, including potential declines in royalty revenues due to generic erosion and partnership uncertainties. Additionally, broader macroeconomic factors, such as tariff volatility, alongside the inherent risks related to antibiotic resistance, compound the negative outlook for Innoviva's financial performance and stock stability.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.